|
Mycobacterium tuberculosis Complex
Read the Chapter
Sliding Table of
Contents on the left of the screen
Tables and Figures
Figure 1.
Monitoring Patients Receiving Isoniazid
Table 1. Dosages, Pharmacokinetics and Minimal
Inhibitory Concentrations of Antituberculosis Medications
Table 2. First Line Drugs [Download PDF]
Table 3. Second Line Drugs [Download PDF]
Table 4. Drug Regimen For
Culture-positive Pulmonary tuberculosis [Download PDF]
Table 5. Selected Treatment Regimens for Drug-Resistant tuberculosis. [Download PDF]
Table 6.
Dosing Recommendations in Patients
Receiving Chronic Hemodialysis [Download PDF]
Table 7. Criteria for Positive Tuberculin Skin Test, By Risk Group [Download PDF]
Table 8. Recommended Treatment Regimens for LTBI [Download PDF]
Vignettes
Editorial Comment: Sun, HY. Efavirenz-based
antiretroviral therapy is a better choice for HIV-positive patients treated
with rifampicin-based antituberculous therapy. 2009.
Review
Article: Drobniewski FA,
Caws M, Gibson A, Young D. Modern laboratory diagnosis of tuberculosis. Lancet
Infect Dis. 2003 Mar;3:141-7.
Review
Article:
Pillay T, Khan M, Moodley J, Adhikari M, Coovadia H. Perinatal tuberculosis
and HIV-1: considerations for resource-limited settings. Lancet Infect Dis.
2004 Mar;4(3):155-65.
Review Article: CDC. Managing
Interactions in the Treatment of HIV Related Tuberculosis. 2007.
Available from URL:
http://www.cdc.gov.tb/TB-HIV_Drugs/default.htm.
Review Article: Meintjes G, et al.
Tuberculosis-associated immune reconstitution inflammatory syndrome: case
definitions for use in resource-limited settings. Lancet Infect Dis
2008;8(8):516-523.
Review Article: Mitnick
CD, et.al. Comprehensive Treatment of Extensively Drug-Resistant
Tuberculosis. N Engl J Med. 2008 Aug 7;359(6):563-74.
Review Article: Jain SK, et al. Why
is duration of Tuberculosis therapy so long?: Sterilization or "persisters"
Microbe 2008;3(6):285-292.
Guideline: American Thoracic
Society/Centers for Disease Control and Prevention/Infectious Diseases
Society of America: Controlling Tuberculosis in the United States. Am J
Respir Crit Care Med 2005;172:1169-1227.
Guideline: International Standards for
Tuberculosis Care (Endorsed by IDSA) World Health Organization, 2006.
Guideline: ATS/CDC/IDSA. Practice
Guidelines for the Treatment of Tuberculosis. MMWR 2003;52 (RR-11).
Iseman MD.
Extensively Drug-Resistant Mycobacterium tuberculosis:
Charles Darwin Would Understand. Clin Infect Dis. 2007;45:1415–6.
Ullman A.
Pasteur-Koch: Distinctive Ways of Thinking about Infectious Diseases.
Microbe 2007;2(8):383-387.
Mackowiak PA, et al.
On the Origin of American Tuberculosis.
Clin Infect Dis 2005;41:515-518.
Schultz, M.
Theobald Smith. Emerg Infect Dis. 2008.
Dec; 14:1940-2.
Wirth, T et al.
Mycobacterium tuberculosis and Homo sapiens: Microbiological
and Anthropological Coevolution. Clin Infect Dis. 2009;48:v–vi.
Achkar et al.
Differences in Clinical Presentation among Persons
with Pulmonary Tuberculosis: A Comparison of Documented and Undocumented
Foreign-Born versus US-Born Persons.
Clin
Infect Dis. 2008 Nov 15;47(10):1277-83.
Bakir M et al.
Use of T Cell-based Diagnosis of Tuberculosis
Infection to Optimize Interpretation of Tuberculin Skin Testing for Child
Tuberculosis Contacts.Clin Infect
Dis. 2009 Feb 1;48(3):302-12.
Boulle A.
Outcomes of Nevirapine- and Efavirenz-Based
Antiretroviral Therapy When Coadministered With Rifampicin-Based
Antitubercular Therapy. JAMA
2008;300(5):530-539.
Cattamanchi
A et al.
Clinical Characteristics and Treatment Outcomes of
Patients with Isoniazid-monoresistant Tuberculosis.Clin
Infect Dis. 2009 Jan 15;48(2):179-85.
Christie LJ, et al.
Diagnostic Challenges of Central Nervous System
Tuberculosis. Emerg Infect Dis 2008;14:1473-1475.Danchaivijitr N, et al.
Diagnostic Accuracy of MR Imaging in Tuberculosis
Spondylitis. Journal of the Medical Association of Thailand.
2007:90(8):1581-1589.
Finnell SM et al.
Latent Tuberculosis Infection in Children: A Call for
Revised Treatment Guidelines. Pediatrics. 2009
Mar;123(3):816-22.
Forgacs P, Wengenack NL, et al.
Tuberculosis and trimethoprim-sulfamethoxazole.
Antimicrob Agents Chemother. 2009 Nov;53:4789-93.
Gao XF, et al.
Rifapentine vs. rifampicin for the treatment of pulmonary
tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2009
Jul;13:810-9.
Holland DP, Sanders GD, et al.
Costs and Cost-Effectiveness of Four Treatment Regimens
for Latent Tuberculosis Infection. Am J Respir Crit Care Med. 2009
Jun 1;179:1055-60.
Jacob JT, Nguyen TM, Ray SM.
Male genital tuberculosis. Lancet Infect Dis.
2008 May;8:335-42.
Kwon et al.
Treatment Outcomes for HIV-uninfected Patients with
Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Clin Infect Dis. 2008 Aug
15;47(4):496-502
Lighter, J. et al.
Latent Tuberculosis Diagnosis in Children by Using the
QuantiFERON-TB Gold In-Tube Test.
PEDIATRICS Vol. 123 No. 1 January 2009, pp. 30-37
(doi:10.1542/peds.2007-3618)
McIlleron H, Willemse M, et al.
Isoniazid plasma concentrations in a cohort of South
African children with tuberculosis: implications for international pediatric
dosing guidelines. Clin Infect Dis. 2009 Jun 1;48:1547-53.
Mitnick CD, et al.
Comprehensive Treatment of Extensively Drug-Resistant
Tuberculosis. N Engl J Med 2008;359:563-574.
Pai M, et al.
Systematic Review: T-Cell-based assays for the Diagnosis
of Latent Tuberculosis Infection: An Update. Ann Intern Med
2008;149:177-184.
Pai, M, Ramsay, O'Brien R.
Table:
Evidence-Based Tuberculosis Diagnosis.
PLoS Medicine |
www.plosmedicine.org 2008; 5:e156.
Park SH, Yang SK, et al.
Prospective Randomized Trial of Six-Month Versus
Nine-Month Therapy for Intestinal Tuberculosis.
Antimicrob Agents Chemother. 2009 Oct;53:4167-71.
Thee S, et al.
Ethambutol in paediatric tuberculosis: aspects of
ethambutol serum concentration, efficacy and toxicity in children.
Int J Tuberc Lung Dis 2007;11:965-971.
Thee S, et
al.
Rifampicin Serum Levels in Childhood Tuberculosis.
Int J Tuberc Lung Dis. 2009 Sep;13:1106-11.
Tovar M, et al.
Improved diagnosis of pleural tuberculosis using the
microscope-observation drug-susceptibility technique. Clin Infect
Dis. 2008;46:909-12.
Ziakas PD,
Mylonakis E.
4 months of rifampin compared with 9 months of
isoniazid for the management of latent tuberculosis infection: a
meta-analysis and cost-effectiveness study that focuses on compliance and
liver toxicity.
Clin Infect Dis. 2009 Dec 15;49:1883-9.
Alffenaar JWC, et al.
Pharmacokinetics of Moxifloxacin in Cerebrospinal
Fluid and Plasma in Patients with Tuberculous Meningitis.
Clin Infect Dis 2009;49:1080-1082.Karim SSA, et al. Concurrent Antiretroviral/TB Treatment Decreases
Mortality in HIV Patients.
CAPRISA Newsletter
September 2008.
Karim SS.
Timing of initiation of antiretroviral drugs during
tuberculosis therapy. N Engl J Med 2010;362;(8):697-706.
Cain KP, et al.
An Algorithm for Tuberculosis Screening and Diagnosis
in People with HIV. N Engl J Med 2010;362(8):707-716.
Boehme CC, et al.
Rapid Molecular Detection of Tuberculosis and Rifampin
Resistance. New Engl J Med 2010:Epub ahead of publication.
Small PM, et al.
Tuberculosis Diagnosis - Time for a Game Change.
New Engl J Med
2010:Epub ahead of publication.
Low DE.
Fluoroquinolones for Treatment of Community-Acquired
Pneumonia and Tuberculosis: Putting the Risk of Resistance into Perspective.
Clin Infect Dis 2009;48:1361-1363.
McGrath EE, et al.
Diagnostic Tests for Tuberculosis pleural effusion.
Eur J Clin Microbiol Infect Dis 2010;29:1187-1193.
Martinson NA, et al.
New regimens to prevent Tuberculosis in adults with HIV
infection. NEJM. 2011 July 7 ;365:11-20.
Authors
Dr. Chi Chiu
Leung,
Dr. Kwok Chiu Chang,
Hsin-Yun Sun, M.D.,
Charles L. Daley, M.D.
Previous Editions:
Charles L. Daley, M.D., Henry F. Chambers, M.D.
|
www.antimicrobe.org